19637348

Source:http://linkedlifedata.com/resource/pubmed/id/19637348

Download in:

Switch to

Custom View

Named Graph Language Inference

Statements in which the resource exists as a subject.
Predicate	Object
rdf:type	pubmed:Citation
lifeskim:mentions	umls-concept:C0013216, umls-concept:C0030705, umls-concept:C0278512, umls-concept:C0684224, umls-concept:C1516477, umls-concept:C1518321, umls-concept:C1883712
pubmed:issue	22
pubmed:dateCreated	2009-11-10
pubmed:abstractText	The addition of liposomal muramyl tripeptide phosphatidylethanolamine (MTP-PE) to chemotherapy has been shown to improve overall survival in patients with nonmetastatic osteosarcoma (OS). The authors report the results of addition of liposomal MTP-PE to chemotherapy for patients with metastatic OS.
pubmed:grant	http://linkedlifedata.com/resource/pubmed/grant/P01 CA106450-01A19002, http://linkedlifedata.com/resource/pubmed/grant/U10 CA098413-05, http://linkedlifedata.com/resource/pubmed/grant/U10 CA098543-06, http://linkedlifedata.com/resource/pubmed/grant/U10 CA98413, http://linkedlifedata.com/resource/pubmed/grant/U10 CA98543
pubmed:language	eng
pubmed:journal	http://linkedlifedata.com/resource/pubmed/journal/0374236
pubmed:citationSubset	AIM
pubmed:chemical	http://linkedlifedata.com/resource/pubmed/chemical/Acetylmuramyl-Alanyl-Isoglutamine, http://linkedlifedata.com/resource/pubmed/chemical/Immunologic Factors, http://linkedlifedata.com/resource/pubmed/chemical/Phosphatidylethanolamines, http://linkedlifedata.com/resource/pubmed/chemical/muramylNAc-Ala-isoGln-Lys-tripeptide...
pubmed:status	MEDLINE
pubmed:month	Nov
pubmed:issn	0008-543X
pubmed:author	pubmed-author:BetcherDonna LDL, pubmed-author:ChenZhengjiaZ, pubmed-author:Children's Oncology Group, pubmed-author:ChouAlexander JAJ, pubmed-author:ConradErnest UEU3rd, pubmed-author:GHIGIEE, pubmed-author:KleinermanEugenie SES, pubmed-author:KrailoMark DMD, pubmed-author:MeyersPaul APA, pubmed-author:NiederMichael LML, pubmed-author:WeinerMichael AMA, pubmed-author:WellsRobert JRJ, pubmed-author:WomerRichard BRB
pubmed:issnType	Print
pubmed:day	15
pubmed:volume	115
pubmed:owner	NLM
pubmed:authorsComplete	Y
pubmed:pagination	5339-48
pubmed:dateRevised	2011-9-26
pubmed:meshHeading	pubmed-meshheading:19637348-Acetylmuramyl-Alanyl-Isoglutamine, pubmed-meshheading:19637348-Adolescent, pubmed-meshheading:19637348-Adult, pubmed-meshheading:19637348-Antineoplastic Combined Chemotherapy Protocols, pubmed-meshheading:19637348-Bone Neoplasms, pubmed-meshheading:19637348-Child, pubmed-meshheading:19637348-Child, Preschool, pubmed-meshheading:19637348-Disease-Free Survival, pubmed-meshheading:19637348-Drug Administration Schedule, pubmed-meshheading:19637348-Female, pubmed-meshheading:19637348-Humans, pubmed-meshheading:19637348-Immunologic Factors, pubmed-meshheading:19637348-Infant, pubmed-meshheading:19637348-Infant, Newborn, pubmed-meshheading:19637348-Male, pubmed-meshheading:19637348-Neoplasm Metastasis, pubmed-meshheading:19637348-Osteosarcoma, pubmed-meshheading:19637348-Phosphatidylethanolamines, pubmed-meshheading:19637348-Survival Analysis
pubmed:year	2009
pubmed:articleTitle	Addition of muramyl tripeptide to chemotherapy for patients with newly diagnosed metastatic osteosarcoma: a report from the Children's Oncology Group.
pubmed:affiliation	Department of Pediatrics, Memorial Sloan-Kettering Cancer Center, New York, NY 10065, USA.
pubmed:publicationType	Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, Clinical Trial, Phase III, Research Support, N.I.H., Extramural